Filing Overview
Priveterra Acquisition Corp. filed this Form 8-K on June 21, 2023, under Item 8.01, regarding its proposed business combination with AEON Biopharma, Inc. The filing supplements the definitive proxy statement filed May 12, 2023.
Business Context and Reporting Period
Priveterra is a special purpose acquisition company seeking stockholder approval for its proposed business combination with AEON Biopharma. The filing does not report operating results for AEON or Priveterra and is not a periodic financial statement filing.
Meeting and Transaction Update
- The special meeting originally scheduled for June 21, 2023, was adjourned to June 26, 2023, at 12:00 p.m. Eastern Time, to allow additional time to engage with stockholders.
- The meeting will be held virtually through the stated webcast address.
- Stockholders who previously voted and do not wish to change their vote do not need to take action.
- Stockholders of record as of April 11, 2023, remain eligible to vote, even if they subsequently sold their shares.
- Stockholders may withdraw previously submitted redemption requests before the rescheduled meeting by requesting return of their shares from the transfer agent.
- The location, record date, redemption deadline, and other proposals were unchanged.
Financial Metrics and Capitalization
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, cash, liquidity, or other financial metrics. No guidance or financial forecast is updated in this filing.
Material Changes, Outlook, and Risks
- The material change is the adjournment of the special meeting and the related proxy supplement.
- The filing continues to describe the proposed AEON business combination as subject to stockholder consideration and approval; the filing does not state that the transaction has closed.
- Forward-looking statements concerning the transaction, AEON, pro forma matters, and future performance are subject to risks and uncertainties.
- Referenced risks include those in Priveterra’s IPO prospectus, the definitive proxy statement, the related S-4 registration statement, and other SEC filings.
- Completion of the transaction and the ultimate level of redemptions remain important contingencies. The filing does not provide an updated redemption amount or transaction funding level.
Key Facts to Verify
- Whether stockholders approved the business combination at the rescheduled June 26, 2023 meeting.
- The number and value of shares redeemed and the resulting cash available to the combined company.
- Any subsequent amendments to the merger agreement, transaction structure, or closing conditions.
- AEON Biopharma’s financial condition, liquidity needs, operating results, and regulatory or clinical development risks in the definitive proxy statement and related filings.
- Whether and when the business combination ultimately closed.